H7N9

Virax Biolabs Group Limited Introduces Avian Influenza A Virus Real-Time PCR Test Kit

Retrieved on: 
Tuesday, March 7, 2023
H3, Poultry, Infection, H10, PCR, Diagnosis, Influenza A virus, H7N9, AIV, European, H5N1, Human, Livestock, Virus, Viral, CE, Vaccine, H5, H7

LONDON, March 7, 2023 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative diagnostics company focused on the prevention, detection, and diagnosis of viral diseases, announced today that it has entered into an agreement for the distribution of an Avian Influenza A Virus ("AIV") real-time PCR test kit to markets accepting the CE mark, namely the European Union.

Key Points: 
  • LONDON, March 7, 2023 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative diagnostics company focused on the prevention, detection, and diagnosis of viral diseases, announced today that it has entered into an agreement for the distribution of an Avian Influenza A Virus ("AIV") real-time PCR test kit to markets accepting the CE mark, namely the European Union.
  • The test kit is for the detection and differentiation of ribonucleic acid from AIV and the H5, H7 and H9 subtypes, including the H5N1 strain currently spreading in Europe.
  • The test kit is for use in laboratory settings and can help healthcare professionals accurately identify an AIV infection.
  • With a real-time PCR test kit poised to accurately and reliably detect AIV, including the deadly H5N1 strain, we expect to facilitate rapid and potentially life-saving interventions especially in vulnerable jurisdictions."

Genentech Announces FDA Approval of Xofluza to Treat Influenza in Children Aged Five and Older

Retrieved on: 
Thursday, August 11, 2022
Biotechnology, FDA, Infectious Diseases, Health, Pharmaceutical, FDA, Allergy, Regulation of tobacco by the U.S. Food and Drug Administration, Baylor College of Medicine, Vomiting, Nausea, Ageing, The New England Journal of Medicine, Public health, Laxative, Vitamin, Death, Oseltamivir, The Pediatric Infectious Disease Journal, Center, Microbiology, Baylor University, Shionogi, Diarrhea, Hoffmann-La Roche, Patient, Infection, Roche, COVID-19, Sinusitis, Biotechnology, RO, Post-exposure prophylaxis, Antacid, Headache, Shanda, Korea Disease Control and Prevention Agency, Tell, ROG, New Drug Application, Food, Pediatrics, Breast milk, Bronchitis, Vaccine, Fine chemical, Pharmaceutical industry, Toy, Birth control, Poultry, Generic drug, Genentech, H7N9

Additionally, the FDA approved Xofluza for the prevention (post-exposure prophylaxis) of influenza in children aged five to less than 12 years of age following contact with someone with influenza.

Key Points: 
  • Additionally, the FDA approved Xofluza for the prevention (post-exposure prophylaxis) of influenza in children aged five to less than 12 years of age following contact with someone with influenza.
  • However, in the U.S. 2018-2019 influenza season, there were more than 6 million illnesses, thousands of hospitalizations and more than 100 deaths for children aged five to 17 caused by influenza.
  • Todays FDA approval provides children with a single-dose antiviral option, Xofluza, to treat influenza."
  • BLOCKSTONE evaluated Xofluza compared with placebo as a preventive treatment for household members (adults and children) who were living with someone with influenza.

Clinical Evaluation of LeSoleil Against COVID-19

Retrieved on: 
Thursday, January 6, 2022
Nuclear, Respiration, CCL8, Respiratory tract, Severe acute respiratory syndrome coronavirus 2, COVID-19, Drug discovery, Omicron, Assay, Heme, Acquisition, Oxidative stress, H5N1, Research, Patient, Biomedical Research, IL-6, PCT, Delta, HO-1, Peroxisome, Drug design, Health, Infection, Creatinine, Inflammation, Economic development, International Drug Policy Consortium, Incidence, Interleukin 1 beta, Lymphocyte, Protocol, R, Death, Warfarin necrosis, Nrf2 internal ribosome entry site (IRES), Pharmaceutical industry, Vaccine, H7N9, SunTrap, H1N1

The Suntrap team believes that the prevention and treatment of COVID-19 should focus on the development of multi-targeted and broad-spectrum anti-coronavirus drugs.

Key Points: 
  • The Suntrap team believes that the prevention and treatment of COVID-19 should focus on the development of multi-targeted and broad-spectrum anti-coronavirus drugs.
  • Based on the clinical symptoms and pathogenic mechanism of patients infected with SARS-CoV-2, the Suntrap research team optimized and developed different clinical protocols.
  • LeSoleil broad-spectrum anti-coronavirus protective and therapeutic spray can cope with the prevention and treatment of SARS-CoV-2 and variant strains (e.g., Delta and Omicron.).
  • To further in-depth clinical research of LeSoleil anti-SARS-CoV-2 drugs, and deter COVID-19 as an obstacle for social stability, economic development and human health, Suntrap recruits qualified clinical research institutions around the world to carry out clinical evaluation studies on the efficacy of the LeSoleil broad-spectrum anti-coronavirus drug series against mutant strains of SARS-CoV-2.

Enesi Pharma Enters Agreement with National Institutes of Health to Evaluate ImplaVax®-enabled Flu Vaccines

Retrieved on: 
Tuesday, October 19, 2021
University, Biomedical Advanced Research and Development Authority, Pirbright Institute, Innovate UK, NIAID, Infection, Assistant, Development, Office of the Assistant Secretary for Preparedness and Response, Drive, WRAIR, Department, Coronavirus Scientific Advisory Board (Turkey), United States Department of Health and Human Services, BARDA, Performance-based contracting, NIH, National Institute, Vaccine, Vaccination, Bill, Saono Enesi, APHA, National Institute of Allergy and Infectious Diseases, H7N9, Patient, Imperial College London, Innovation, Partnership, Bill & Melinda Gates Foundation, Global health, Walter Reed Army Institute of Research, Allergy, Safety, Inflammation, Government, Pharmaceutical industry, Medical device

ImplaVax-enabled vaccination products leverage Enesi's innovative unit solid-dose, thermally stable formulation and needle-free delivery technologies, and are applicable across all vaccine formats.

Key Points: 
  • ImplaVax-enabled vaccination products leverage Enesi's innovative unit solid-dose, thermally stable formulation and needle-free delivery technologies, and are applicable across all vaccine formats.
  • Under NIAID's suite of preclinical services, NIAID-funded contractors will test the ImplaVax formulation in animal model challenge studies against flu viruses.
  • NIAID and its funded researchers are conducting preclinical and clinical studies on various investigational pandemic flu vaccines.
  • Enesi Pharma is developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax technologies.

Enesi Pharma Enters Agreement with National Institutes of Health to Evaluate ImplaVax®-enabled Flu Vaccines

Retrieved on: 
Tuesday, October 19, 2021
University, Biomedical Advanced Research and Development Authority, Pirbright Institute, Innovate UK, NIAID, Infection, Assistant, Development, Office of the Assistant Secretary for Preparedness and Response, Drive, WRAIR, Department, Coronavirus Scientific Advisory Board (Turkey), United States Department of Health and Human Services, BARDA, Performance-based contracting, NIH, National Institute, Vaccine, Vaccination, Bill, Saono Enesi, APHA, National Institute of Allergy and Infectious Diseases, H7N9, Patient, Imperial College London, Innovation, Partnership, Bill & Melinda Gates Foundation, Global health, Walter Reed Army Institute of Research, Allergy, Safety, Inflammation, Government, Pharmaceutical industry, Medical device

ImplaVax-enabled vaccination products leverage Enesi's innovative unit solid-dose, thermally stable formulation and needle-free delivery technologies, and are applicable across all vaccine formats.

Key Points: 
  • ImplaVax-enabled vaccination products leverage Enesi's innovative unit solid-dose, thermally stable formulation and needle-free delivery technologies, and are applicable across all vaccine formats.
  • Under NIAID's suite of preclinical services, NIAID-funded contractors will test the ImplaVax formulation in animal model challenge studies against flu viruses.
  • NIAID and its funded researchers are conducting preclinical and clinical studies on various investigational pandemic flu vaccines.
  • Enesi Pharma is developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax technologies.